Literature DB >> 6327437

Protein phosphatase-1 and -2A activities in heart, liver, and skeletal muscle extracts from control and diabetic rats.

J G Foulkes, L S Jefferson.   

Abstract

Protein phosphatase activities have recently been classified into two major groups of enzymes termed type 1 and type 2. In the present study, this classification scheme has been used to explore the types of protein phosphatase activities found in rat heart, liver, and skeletal muscle, and to determine the type of protein phosphatase activity affected by diabetes. Protein phosphatase activities have been measured under conditions designed to minimize the influence of effectors of these enzymes, and a thermostable protein phosphatase inhibitor, termed inhibitor-2, has been used as a probe to specifically inhibit type 1 protein phosphatase. The specific activity of protein phosphatase-1 in extracts of heart, liver, and skeletal muscle from control rats ranged between 0.34 and 0.44 U/mg protein. The specific activity of a type 2 enzyme, termed protein phosphatase-2A, was approximately the same as protein phosphatase-1 in the case of skeletal muscle extracts, but was about 50% higher than type 1 in extracts from liver and heart. The only significant effect of diabetes was on hepatic protein phosphatase-1 in which a 50% decrease in specific activity was noted. Therefore, the effect of diabetes appeared to be confined to protein phosphatase-1 and this effect was only seen in liver.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327437     DOI: 10.2337/diab.33.6.576

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  Insulin action on protein phosphatase-1 activation is enhanced by the antidiabetic agent pioglitazone in cultured diabetic hepatocytes.

Authors:  S Pugazhenthi; R L Khandelwal
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

2.  Effects of diabetes, vanadium, and insulin on glycogen synthase activation in Wistar rats.

Authors:  Sabina Semiz; Chris Orvig; John H McNeill
Journal:  Mol Cell Biochem       Date:  2002-02       Impact factor: 3.396

3.  Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo.

Authors:  Askar Mohammad; Jian Wang; John H McNeill
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

4.  Deficiency in phosphorylase phosphatase activity despite elevated protein phosphatase type-1 catalytic subunit in skeletal muscle from insulin-resistant subjects.

Authors:  B L Nyomba; D L Brautigan; K K Schlender; W Wang; C Bogardus; D M Mott
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

5.  Purification and the immunological characterization of rat protein phosphatase 2A: enzyme levels in diabetic liver and heart.

Authors:  S R Jaspers; T B Miller
Journal:  Mol Cell Biochem       Date:  1991-03-13       Impact factor: 3.396

6.  Effects of diabetes on the expressed and total activities of 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver in vivo. Reversal by insulin treatment.

Authors:  R A Easom; V A Zammit
Journal:  Biochem J       Date:  1985-09-15       Impact factor: 3.857

7.  Identification of the molecular basis for phosphorylase hypersensitivity in cultured diabetic cardiomyocytes.

Authors:  J A Buczek-Thomas; T B Miller
Journal:  Mol Cell Biochem       Date:  1995-04-26       Impact factor: 3.396

8.  Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity.

Authors:  Sabina Semiz; John H McNeill
Journal:  Mol Cell Biochem       Date:  2002-07       Impact factor: 3.396

9.  Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo.

Authors:  Leena P Bharath; Ting Ruan; Youyou Li; Anindita Ravindran; Xin Wan; Jennifer Kim Nhan; Matthew Lewis Walker; Lance Deeter; Rebekah Goodrich; Elizabeth Johnson; Derek Munday; Robert Mueller; David Kunz; Deborah Jones; Van Reese; Scott A Summers; Pon Velayutham Anandh Babu; William L Holland; Quan-Jiang Zhang; E Dale Abel; J David Symons
Journal:  Diabetes       Date:  2015-08-07       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.